Form 8-K - Current report:
SEC Accession No. 0001213900-25-045970
Filing Date
2025-05-20
Accepted
2025-05-20 16:15:37
Documents
14
Period of Report
2025-05-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242929-8k_neuphoria.htm   iXBRL 8-K 25454
2 PRESS RELEASE DATED MAY 20, 2025 ea0242929ex99-1_neuphoria.htm EX-99.1 13386
3 GRAPHIC image_001.jpg GRAPHIC 4464
  Complete submission text file 0001213900-25-045970.txt   213913

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE neup-20250520.xsd EX-101.SCH 3023
5 XBRL LABEL FILE neup-20250520_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE neup-20250520_pre.xml EX-101.PRE 22364
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0242929-8k_neuphoria_htm.xml XML 3567
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Filer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-41157 | Film No.: 25968982
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)